Management and Clinical Outcomes of Patients with Advanced Ovarian Cancer in Routine Clinical Practice in Spain : The OVOC Study
Quindós-Varela, M. (Instituto de Investigación Biomédica de A Coruña)
Soto de Prado-Otero, D. (Hospital Clínico Universitario de Valladolid)
Gallego, A. (Hospital Universitario La Paz (Madrid))
García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Guerra, Eva (Hospital Universitario Ramón y Cajal (Madrid))
Estévez-García, Purificación (Instituto de Biomedicina de Sevilla)
Barretina-Ginesta, Maria-Pilar (Institut Català d'Oncologia)
Borraz, P. (Roche Farma S.A.)
González-Martín, A. (Clínica Universidad de Navarra)
Rubio, Maria Jesus (Hospital Universitario Reina Sofía (Córdoba, Espanya))
Universitat Autònoma de Barcelona

Data:	2025
Resum:	Introduction: The OVOC study was carried out to evaluate the management and clinical evolution of patients with advanced ovarian cancer (AOC) in routine clinical practice in Spain. Methods: A retrospective study was made in women diagnosed with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (FIGO IIIB-IV) who had received at least one line of treatment between 2013 and 2016, before the establishment of poly ADP ribose polymerase (PARP) inhibitors as first-line treatment. Results: A total of 400 patients (median age: 61. 7 years; FIGO IIIC: 60. 0%; high-grade serous carcinoma: 75. 0%) received a median of two therapy lines. Primary and interval debulking surgery was performed in 37. 0% and 54. 3% of the patients. Germline BRCA1 and BRCA2 mutations were found in 16. 2% and 12. 0% of the patients. The median progression-free survival (PFS) from the start of the first-/second-/third-line of treatment was 14. 2/8. 7/4. 5 months. The median treatment-free interval (TFI) to the start of the second line was 9. 9 months. The median overall survival (OS) was 42. 6 months. At first relapse, 65. 9% of the patients were platinum-sensitive and 34. 1% platinum-resistant. Biologic therapies were administered in 25. 2% of the platinum-sensitive and 16. 2% of the platinum-resistant patients. Patients harboring BRCA mutations had a lower risk of progression/relapse after the first (BRCA1 and BRCA2 mutation versus native: p < 0. 0001) and second line (BRCA1 and BRCA2 mutation versus native: p = 0. 021 and p = 0. 037, respectively). Patients with BRCA2 mutations had a lower mortality risk than those without (p = 0. 015). The median PFS was significantly higher in patients receiving targeted therapy in the first (17. 4 versus 11. 6 months; p = 0. 039) and second line (11. 1 versus 7. 8 months; p < 0. 001). Conclusion: This study provides real-world data on therapeutic management and outcomes in AOC patients in Spain. A longer PFS was achieved in patients receiving targeted therapies. BRCA1/2 mutations were a favorable prognostic factor for PFS and BRCA2 mutation for OS.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Advanced ovarian cancer ; Biologic therapies ; Clinical outcomes ; Treatment patterns
Publicat a:	Oncology and Therapy, Vol. 13 Núm. 3 (september 2025) , p. 631-648, ISSN 2366-1089

DOI: 10.1007/s40487-025-00347-1
PMID: 40392495

18 p, 1.1 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d’Investigació i Innovació Parc Taulí (I3PT)
Articles > Articles de recerca
Articles > Articles publicats